Help ?

IGMIN: We're glad you're here. Please click 'create a new query' if you are a new visitor to our website and need further information from us.

If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click 'take me to my Query.'

Browse by Subjects

Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.

Members

Our vision is to be a bridge for scientific fields, fostering dialogue and rapid progress.

Articles

Our vision is to be a bridge for scientific fields, fostering dialogue and rapid progress.

Explore Content

Our vision is to be a bridge for scientific fields, fostering dialogue and rapid progress.

Identify Us

Our vision is to be a bridge for scientific fields, fostering dialogue and rapid progress.

IgMin Corporation

Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.

Publications Support
[email protected]
E-Books Support
[email protected]
Webinars & Conferences Support
[email protected]
Content Writing Support
[email protected]
IT Support
[email protected]

Search

Explore Section

Content for the explore section slider goes here.

Abstract

Abstract at IgMin Research

Our vision is to be a bridge for scientific fields, fostering dialogue and rapid progress.

Medicine Group Case Report Article ID: igmin228

Levetiracetam-induced Rhabdomyolysis - A Rare Complication

Neurology Clinical Medicine DOI10.61927/igmin228 Affiliation

Affiliation

    Ayisha Farooq Khan, Section of Neurology, Department of Medicine, Aga Khan University, National Stadium Road, Karachi, Pakistan, Email: [email protected]

11.5k
VIEWS
267
DOWNLOADS
Connect with Us

Abstract

Background: Levetiracetam is an anti-epileptic drug that works by modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein 2A. Levetiracetam is generally well tolerated. Common side effects of levetiracetam include lethargy, drowsiness, headaches, and mood changes. Rhabdomyolysis and an increase in Creatine Kinase (CK) levels are one of the rarely reported effects of levetiracetam.
Case presentation: We present a case of a 20-year-old patient with previously known epilepsy (non-compliant with medicine) who presented with a seizure. The patient was given 1 gram of levetiracetam in the emergency department and was kept at a maintenance dose of 500 mg twice a day. The workup revealed acute kidney injury and raised levels of creatinine kinase that peaked at 19,757 IU/L 72 hours after levetiracetam was started. Levetiracetam was later switched to lamotrigine and aggressive intravenous hydration was done. Gradual improvement of CK level was noted accompanied by improvement in renal function.
Conclusion: Only a few cases of levetiracetam-induced rhabdomyolysis have been reported worldwide. Our case report highlights the importance of monitoring creatinine and CK levels while treating patients with levetiracetam as rhabdomyolysis can be asymptomatic with a rise in CK levels only.

Figures

References

    1. Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. Am J Case Rep. 2020 Oct 28;21:e926064. doi: 10.12659/AJCR.926064. PMID: 33112844; PMCID: PMC7603803.
    2. Tiglis M, Hurmuzache T, Bologa C, Neagu TP, Mirea L, Grintescu IM. Rhabdomyolysis-Induced Acute Renal Injury in a Schizophrenic Patient. J Crit Care Med (Targu Mures). 2020 Nov 7;6(4):249-252. doi: 10.2478/jccm-2020-0032. PMID: 33200097; PMCID: PMC7648442.
    3. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 Jul 2;361(1):62-72. doi: 10.1056/NEJMra0801327. Erratum in: N Engl J Med. 2011 May 19;364(20):1982. PMID: 19571284.
    4. Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015 Spring;15(1):58-69. PMID: 25829882; PMCID: PMC4365849.
    5. Shahbaz N, Younus SM, Khan SA, Ain Q-, Khan MA, Memon MH. Levetiracetam Induced Increase in Creatine Phosphokinase Levels. J Coll Physicians Surg Pak. 2017 Mar;27(3):S63-S64. PMID: 28302251.
    6. Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy Behav Case Rep. 2014 Sep 16;2:152-155. doi: 10.1016/j.ebcr.2014.08.001. PMID: 25667895; PMCID: PMC4308062.
    7. Al-Quliti K, Alhujeily RM. Acute kidney injury with levetiracetam in patient with epilepsy: a case report. Case Reports in Clinical Medicine. 2022;11(3):48-54.
    8. Di Lorenzo R, Li Y. Rhabdomyolysis associated with levetiracetam administration. Muscle Nerve. 2017 Jul;56(1):E1-E2. doi: 10.1002/mus.25548. Epub 2017 Mar 23. PMID: 28039868.
    9. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-523. doi: 10.2147/ndt.s2937. PMID: 18830435; PMCID: PMC2526377.
    10. Carnovale C, Gentili M, Antoniazzi S, Clementi E, Radice S. Levetiracetam-induced rhabdomyolysis: Analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database. Muscle Nerve. 2017 Dec;56(6):E176-E178. doi: 10.1002/mus.25972. Epub 2017 Sep 30. PMID: 28888059.
    11. Kim H, Jo S, Park KW, Han SH, Lee SA. A Case of Phenytoin-induced Rhabdomyolysis in Status Epilepticus. J Epilepsy Res. 2016 Jun 30;6(1):36-38. doi: 10.14581/jer.16007. PMID: 27390679; PMCID: PMC4933680.
    12. Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J. 1993 May;69(811):333-336. doi: 10.1136/pgmj.69.811.333. PMID: 8393995; PMCID: PMC2399808.
    13. Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. Med J Aust. 2013;199(9):624-625.
    14. Kazmi JS, Albarghouthy N, Ramsaywak R. Levetiracetam-Induced Rhabdomyolysis Reversed by Discontinuation: A Case Report. Cureus. 2023;15(11):e48955. doi: 10.7759/cureus.48955. PMID: 38111426; PMCID: PMC10726084.
    15. Nizamudeen K, Sabu ST, Dharan SS. An overview of the rare and life-threatening adverse effects of levetiracetam. World Journal of Pharmaceutical Research. 9:649-670. DOI: 10.20959/wjpr202011-18761

Similar Articles